1-20 of 49055 Search Results for

lung-cancer

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (10_Supplement): A005.
Published: 15 May 2022
...Hannah Wollenzien; Yohannes Afeworki; Michael S. Kareta Small Cell Lung Cancer (SCLC) is often a heterogeneous tumor, where multiple populations of phenotypically different cells exist and contribute differentially to tumor dynamics. This tumor is characterized by a very low 2- year survival rate...
Journal Articles
Cancer Res (2022) 82 (10_Supplement): A018.
Published: 15 May 2022
...Jun Xia; Mu Lin; Zhuoyi Song; Gail Fernandes; Susan Rosenberg; Chris Amos Lung cancer is a multifactorial disease caused by both environmental exposures and genetic factors. Genome and transcriptome-wide association studies (GWAS and TWAS) successfully identified many genetic variants and candidate...
Journal Articles
Cancer Res (2022) 82 (10_Supplement): A040.
Published: 15 May 2022
...Xiao Fu; Ajay Bhargava; Sasha Bailey; Dhruva Biswas; Carlos Martinez Ruiz; Sunil Kumar; Paul French; Nicholas McGranahan; Charles Swanton; Paul A. Bates; Erik Sahai Lung cancer is a leading cause of cancer-related deaths. Despite enhanced characterization of genomic complexity and intra-tumor...
Journal Articles
Cancer Res (2022) 82 (8): 1633–1645.
Published: 15 April 2022
... insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effects due to their strong inhibition of wild-type (WT) EGFR...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (10_Supplement): IA016.
Published: 15 May 2022
...Andriy Marusyk Background . Despite remarkable initial efficacy, targeted therapies eventually fail in advanced lung cancers. This failure reflects the ability of neoplastic populations to adapt to therapy-imposed selection pressures. In principle, disrupting this ability might transform clinical...
Journal Articles
Cancer Res (2022) 82 (6): 972–973.
Published: 15 March 2022
...Jihan K. Osborne; John D. Minna Identifying the cell(s) of origin for lung cancer including detecting their expansion during “field cancerization” and understanding how to therapeutically target them for beneficial chemoprevention is an urgent need. In this issue of Cancer Research, Yin...
Journal Articles
Cancer Res (2022) 82 (5): 791–804.
Published: 03 March 2022
... that is mutated in 5% to 11% of lung cancers. Although recent studies have elucidated the mechanism underlying dysregulation of the switch/sucrose non-fermentable (SWI/SNF) complexes in cancers, the significance of ARID1A loss and its implications in lung cancers remain poorly defined. This study investigates how...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (2): 199–209.
Published: 18 January 2022
... with leukemia and some solid tumors, the relationship between CH and lung cancer remains largely unknown. To help clarify this relationship, we analyzed whole-exome sequencing (WES) data from 1,958 lung cancer cases and controls. Potential CH mutations were identified by a set of hierarchical filtering criteria...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (3): 472–483.
Published: 02 February 2022
... Asher; Michael H. Roehrl; Juan Qiu; Elisa de Stanchina; Travis J. Hollmann; Richard P. Koche; Triparna Sen; John T. Poirier; Charles M. Rudin Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (2): 248–263.
Published: 18 January 2022
.... Oser Neuroendocrine to nonneuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20% to 25% of SCLCs harbor loss-of-function (LOF) NOTCH mutations. Previous studies demonstrated that NOTCH functions as a SCLC tumor suppressor...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (1): 18–20.
Published: 04 January 2022
... EGFR mutations, one of the most prevalently observed oncogenic alterations in non–small cell lung cancer (NSCLC) targeted clinically. Currently, numerous efforts have attempted to delay or overcome acquired resistance to EGFR–tyrosine kinase inhibitors (TKI), changing the treatment landscape...
Journal Articles
Cancer Res (2022) 82 (1): 75–89.
Published: 04 January 2022
...Afeez Adekunle Ishola; Chian-Shiu Chien; Yi-Ping Yang; Yueh Chien; Aliaksandr A. Yarmishyn; Ping-Hsing Tsai; Jerry Chieh-Yu Chen; Po-Kuei Hsu; Yung-Hung Luo; Yuh-Min Chen; Kung-Hou Liang; Yuan-Tzu Lan; Teh-Ia Huo; Hsin-I. Ma; Ming-Teh Chen; Mong-Lien Wang; Shih-Hwa Chiou Lung cancers...
Includes: Supplementary data
Images
ARID1A was frequently mutated in human <span class="search-highlight">lung</span> <span class="search-highlight">cancer</span>, and its loss promoted K...
Published: 03 March 2022
Figure 1. ARID1A was frequently mutated in human lung cancer, and its loss promoted KrasG12D-driven lung adenocarcinoma in vivo. A, The frequency of mutations in the ARID1A gene in five clinical cohorts (n = 2,014) of patients with lung cancer. B, Lollipop presents mutations in the ARID1A gene in the clinical cohorts. Green dot, missense mutations; black dot, truncating mutations. C, Images of positive and negative expression of ARID1A in human lung cancers. D, Pie chart demonstrates the distribution of ARID1A expression levels in lung cancer tissues in our clinical cohort (n = 157). E, Schematic diagram of the induction of lung tumors in genetically engineered mouse models. F, Representative images of gross anatomy of lungs of Tp53fl/fl, KrasLSL-G12D (KP) and KrasLSL-G12D; Tp53fl/fl; Ardi1afl/fl (KPAfl/fl) mice. G, Representative images of micro-CT (top) and hematoxylin and eosin–stained lung tissue (bottom) of WT; Arid1afl/fl; Tp53fl/fl, KrasLSL-G12D (KP); Tp53fl/fl; Arid1afl/+ (KPAfl/+) and KrasLSL-G12D; Tp53fl/fl; Arid1afl/fl (KPAfl/fl) mice. H, IHC analysis of TTF-1, P63, ARID1A, and Ki67 in KP and KPAfl/fl tumors. I and J, Comparison of tumor number and area (%) of visible tumor nodes at the surface of lungs across KP, KPAfl/+, and KPAfl/fl groups. Data were analyzed using Welch t test and are presented with mean ± SEM in barplot. K, Comparison of Ki67-positive nucleus between KP and KPAfl/fl tumors. Data were analyzed using Welch t test and are presented with mean ± SEM in barplot. L, Survival analysis of KP, KPAfl/+, and KPAfl/fl tumor-bearing mice. Kaplan–Meier method was used to draft the survival plot. Survival differences between two groups were compared using the two-sided log-rank test (pKP vs. KPAfl/fl < 0.001). Mice that died within 4 weeks after virus delivery were considered to be dead for lung injury and were not included in the survival analysis. *, P < 0.05; **, P < 0.01. NS, not significant; wk, weeks. Figure 1. ARID1A was frequently mutated in human lung cancer, and its loss promoted KrasG12D-driven lung adenocarcinoma in vivo. A, The frequency of mutations in the ARID1A gene in five clinical cohorts (n = 2,014) of patients with lung cancer. B, Lollipop presents mutations in the ARID1A gene in the clinical cohorts. Green dot, missense mutations; black dot, truncating mutations. C, Images of positive and negative expression of ARID1A in human lung cancers. D, Pie chart demonstrates the distribution of ARID1A expression levels in lung cancer tissues in our clinical cohort (n = 157). E, Schematic diagram of the induction of lung tumors in genetically engineered mouse models. F, Representative images of gross anatomy of lungs of Tp53fl/fl, KrasLSL-G12D (KP) and KrasLSL-G12D; Tp53fl/fl; Ardi1afl/fl (KPAfl/fl) mice. G, Representative images of micro-CT (top) and hematoxylin and eosin–stained lung tissue (bottom) of WT; Arid1afl/fl; Tp53fl/fl, KrasLSL-G12D (KP); Tp53fl/fl; Arid1afl/+ (KPAfl/+) and KrasLSL-G12D; Tp53fl/fl; Arid1afl/fl (KPAfl/fl) mice. H, IHC analysis of TTF-1, P63, ARID1A, and Ki67 in KP and KPAfl/fl tumors. I and J, Comparison of tumor number and area (%) of visible tumor nodes at the surface of lungs across KP, KPAfl/+, and KPAfl/fl groups. Data were analyzed using Welch t test and are presented with mean ± SEM in barplot. K, Comparison of Ki67-positive nucleus between KP and KPAfl/fl tumors. Data were analyzed using Welch t test and are presented with mean ± SEM in barplot. L, Survival analysis of KP, KPAfl/+, and KPAfl/fl tumor-bearing mice. Kaplan–Meier method was used to draft the survival plot. Survival differences between two groups were compared using the two-sided log-rank test (pKP vs. KPAfl/fl < 0.001). Mice that died within 4 weeks after virus delivery were considered to be dead for lung injury and were not included in the survival analysis. *, P < 0.05; **, P < 0.01. NS, not significant; wk, weeks. More
Images
Preclinical BET inhibitors impaired the formation and growth of <span class="search-highlight">lung</span> <span class="search-highlight">cancer</span>...
Published: 03 March 2022
Figure 7. Preclinical BET inhibitors impaired the formation and growth of lung cancer organoids. A, Schematic diagram of organoids culture and drug test. B, Organoids established from KP and KPAfl/fl tumors. C and D, Comparison of formation and diameters between KP and KPAfl/fl tumor-derived organoids. Data were analyzed using Student t test and are presented with mean SEM in barplot. E, Comparison of the effect of five BET inhibitors (JQ1, BET762, OTX015, BET726, and BET151) on the formation of KP and KPAfl/fl tumor-derived organoids. Data were analyzed using Welch t test and are presented with mean ± SEM in barplot. F, Comparison of the effect of five BET inhibitors (JQ1, BET762, OTX015, BET726, and BET151) on the viability of KP and KPAfl/fl tumor-derived organoids. The organoids viability across different groups was identified using cell count kit assay. Then, the IC50 value of each group was identified using the normalized response-variable slope according to viability of the organoids. *, P < 0.05; **, P < 0.01. Figure 7. Preclinical BET inhibitors impaired the formation and growth of lung cancer organoids. A, Schematic diagram of organoids culture and drug test. B, Organoids established from KP and KPAfl/fl tumors. C and D, Comparison of formation and diameters between KP and KPAfl/fl tumor-derived organoids. Data were analyzed using Student t test and are presented with mean SEM in barplot. E, Comparison of the effect of five BET inhibitors (JQ1, BET762, OTX015, BET726, and BET151) on the formation of KP and KPAfl/fl tumor-derived organoids. Data were analyzed using Welch t test and are presented with mean ± SEM in barplot. F, Comparison of the effect of five BET inhibitors (JQ1, BET762, OTX015, BET726, and BET151) on the viability of KP and KPAfl/fl tumor-derived organoids. The organoids viability across different groups was identified using cell count kit assay. Then, the IC50 value of each group was identified using the normalized response-variable slope according to viability of the organoids. *, P < 0.05; **, P < 0.01. More
Journal Articles
Cancer Res (2021) 81 (23): 5862–5875.
Published: 01 December 2021
..., we discovered noxious carbon-bound exogenous compounds, such as polycyclic aromatic hydrocarbons (PAH), tobacco-specific nitrosamines, or aromatic amines, in a series of 330 patients with lung cancer in highly variable and unique patterns. The characteristic nature of carbon-bound exogenous compounds...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (8): 1617–1632.
Published: 15 April 2022
... variables in light script. K, Correlation of PTDSS1 expression with patient survival in the TCGA lung adenocarcinoma data set. L, Correlation of PTDSS1 and macrophage marker CD163 expression in breast cancer subtypes in the METABRIC dataset. M, PTDSS1 and CD163 expression in tissue microarrays...
Includes: Supplementary data
Images
Cardiac dysfunction enhances <span class="search-highlight">cancer</span> cell colonization to the <span class="search-highlight">lungs</span> in ATF3-...
Published: 03 May 2022
Figure 3. Cardiac dysfunction enhances cancer cell colonization to the lungs in ATF3-transgenic mice model. A, Schematic experimental timeline for ATF3-transgenic and control mice followed by PyMT cell pulmonary experimental metastasis assay by tail vein injection (TV Inj.) of 2 × 106 cells per mouse; Control (Cont.; n = 3) or ATF3-transgenic (ATF3 tg.; n = 4) female mice. B, Representative image of lung sections stained with H&E. Scale bar, 1,000 µm. C, Number of metastatic lesions in the lungs. D, Average area of the metastatic lesions. Data are presented as mean ±SD. Student t test. *, P < 0.05. Figure 3. Cardiac dysfunction enhances cancer cell colonization to the lungs in ATF3-transgenic mice model. A, Schematic experimental timeline for ATF3-transgenic and control mice followed by PyMT cell pulmonary experimental metastasis assay by tail vein injection (TV Inj.) of 2×106 cells per mouse; Control (Cont.; n = 3) or ATF3-transgenic (ATF3 tg.; n = 4) female mice. B, Representative image of lung sections stained with hematoxylin and eosin (H&E). Scale bar, 1,000 µm. C, Number of metastatic lesions in the lungs. D, Average area of the metastatic lesions. Data are presented as mean ±SD. Student t test. *, P < 0.05. More
Images
CH mutations associated with age and <span class="search-highlight">lung</span> <span class="search-highlight">cancer</span> risk factors.  A,  Sliding...
Published: 18 January 2022
Figure 2. CH mutations associated with age and lung cancer risk factors. A, Sliding window approach showed the mean frequency of mutated samples increasing with age. Mean frequency of mutated samples were calculated in each 5-year-old window with 1-year step. B and C, Spearman correlation ( ... More
Journal Articles
Journal Articles
Cancer Res (2022) 82 (7): 1380–1395.
Published: 01 April 2022
... one lung lobe and were added up. Analysis of CAF subsets and tissue compartments in invasive breast cancer tissue microarrays (TMA) specimens provided by the Cooperative Human Tissue Network and the Cancer Diagnosis Program (other investigators may have received specimens from the same subjects...
Includes: Supplementary data